Skip Navigation



Annals of Oncology Advance Access published online on March 19, 2008
Annals of Oncology, doi:10.1093/annonc/mdn064
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/8/1458    most recent
mdn064v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jacot, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacot, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients

W. Jacot1, B. Colinet1,{dagger}, D. Bertrand1, S. Lacombe2, M.-C. Bozonnat2, J.-P. Daurès2, J.-L. Pujol1,2,* and for the OncoLR health network

1 Thoracic Oncology Unit, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve
2 Department of Statistics and Epidemiology, University Institute for Clinical Research, Université de Montpellier I, Montpellier, France

* Correspondence to: Dr J.-L. Pujol, Centre Hospitalier Universitaire de Montpellier Hôpital Arnaud de Villeneuve, F-34295 Montpellier Cedex 5, France. Fax: +33 4 67 33 61 36; Fax: +33 4 67 33 61 35; E-mail: jl-pujol{at}chu-montpellier.fr

Background: Both quality of life (QoL) and comorbidity influence therapy and prognosis of non-small-cell lung cancer (NSCLC). We previously developed a lung cancer disease-specific simplified comorbidity score (SCS) and demonstrated the prognostic impact of this disease-specific instrument. This study aimed at validating the SCS in a prospective bicentric NSCLC population by measuring its relative prognostic determinant impact taking into account well-established variables such as QoL, performance status (PS), Charlson comorbidity index (CCI) and disease stage.

Patients and methods: Prognostic values of different pretherapeutic features were tested in univariate and multivariate analyses in a population of 301 NSCLC.

Results: Median survival was 17 months. One-third of patients reporting difficulties in their normal daily activities and an overall poor QoL. The following pretreament variables were independent determinants of a shorter overall survival: advanced disease, SCS, Lung Cancer Symptoms Scale global symptoms score, anaemia, hyponatremia, serum alkaline phosphatases level, serum CYFRA 21-1 and serum neuron-specific enolase.

Conclusion: In this extended validation population, the SCS is more informative than the CCI in predicting NSCLC patient outcome as the former is also more disease specific. Combination of both SCS comorbidity score and LSCC QoL yields a more accurate information that conventional analysis of PS.

comorbidities, non-small-cell lung cancer, prognosis, quality of life

{dagger} Present address: Respiratory Diseases Unit, Hôpital Saint Joseph, 6, rue de la Duchère, B-6060 Gilly, Belgium.

Received for publication January 23, 2008. Accepted for publication February 14, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
A. Doucet, G. S. Butler, D. Rodriguez, A. Prudova, and C. M. Overall
Metadegradomics: Toward in Vivo Quantitative Degradomics of Proteolytic Post-translational Modifications of the Cancer Proteome
Mol. Cell. Proteomics, October 1, 2008; 7(10): 1925 - 1951.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.